The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has ...

With the Bengaluru unit's clearance from the USFDA out of the window, investors are now eagerly waiting for regulatory ...

In this exclusive interview, Business Today TV's Sakshi Batra speaks with Siddharth Mittal, CEO & MD of Biocon Limited, about ...

Biocon Limited's quarterly earnings report, debt reduction strategy, R&D investment, and CapEx plans for future growth ...

Shares of Biocon gained over 8 per cent after the US Food and Drug Administration (USFDA) classified its Bengaluru unit as ...

Biocon is a prominent global biopharmaceutical company driven by innovation, specialising in therapies for chronic conditions ...

Bengaluru-based Biocon on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30 ...

Biocon Ltd on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024 on account of higher tax, based on geographical split of profits.

The 17th CPHI and PMEC India Expo in Greater Noida highlights pharma modernization and sustainability, hosting over 2,000 ...

Biocon Q2 Results Live : Biocon has released its Q2 results for the fiscal year 2024, reporting a topline growth of 3.7%, with revenue reaching new heights. However, the company faced a loss of ...

The brokerage maintains its Neutral stance on the stock, as the current valuation captures the earnings upside.

Biocon Academy achieves 100% placement for its 6th batch and concludes 5th edition of MCADDI residential programme for industry: Our Bureau, Bengaluru Thursday, November 14, 2024, ...